![](/wp-content/uploads/2024/04/Screenshot-2024-04-03-at-5.18.13%E2%80%AFPM.png)
$599
Clive Meanwell and Ian Reed Take on the Obesity Market; Novo Initiates Icodec Switching Trial; Mounjaro Faces Continued US Supply Constraints; Amarin’s Vazkepa Exclusivity Extended
A series of cardiometabolic-related news items have been observed from Metsera, Lilly, Novo Nordisk, and Amarin Corporation. Below, FENIX provides highlights and insights for the respective news items.